<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55430">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036632</url>
  </required_header>
  <id_info>
    <org_study_id>201211016</org_study_id>
    <nct_id>NCT02036632</nct_id>
  </id_info>
  <brief_title>Eye Patch Therapy for Central Serous Retinopathy (CSR)</brief_title>
  <official_title>Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Washington University School of Medicine</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First, this study will investigate the viability of 24-hour eye patching as a potential
      treatment modality for CSR. Second, this study will assess a potential physiologic
      explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will
      aid in ameliorating disease severity and disease duration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change in multi-focal ERG response and macular thickness after 24-hour patch therapy in patients with CSR</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study is a prospective control trial that will compare 24-hour eye patch therapy with the current standard of care in patients with central serous retinopathy (CSR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in multi-focal ERG response</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>macular thickness</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Central Serous Retinopathy (CSR)</condition>
  <arm_group>
    <arm_group_label>Eye Patching</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eye Patching</intervention_name>
    <arm_group_label>Eye Patching</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age and older

          -  Both males and females

          -  Patients diagnosed with active central serous retinopathy

          -  Patients who are willing to use an eye patch in the affected eye for 24 hours

          -  Patients who are able to make the follow up appointments as required by the study

        Exclusion Criteria:

          -  Individuals under 18 years of age

          -  Patients with vision less than 20/40 in the unaffected eye.

          -  Patients who are not able to undergo mfERG testing in a realiable manner.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory P Van Stavern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sam Pistorius, COA CCRP</last_name>
    <phone>314-747-5832</phone>
    <email>pistoriuss@vision.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Fischbach, CCRP</last_name>
    <phone>314-286-2946</phone>
    <email>FischbachE@vision.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington Universtiy School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Yom, MD</last_name>
      <phone>314-362-3937</phone>
      <email>yomv@vision.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Earl, MD PhD</last_name>
      <phone>314-362-3937</phone>
      <email>earlj@vision.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Van Stavern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajendra Apte, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prabakar K Rao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
